Sparks commentary - IP Group

TMT

Sparks - IP Group

More on this equity
IP Group (LSE: IPO) – Istesso published encouraging data
Published by Milosz Papst

IP Group announced that its portfolio company Istesso published encouraging data in the peer reviewed monthly, The Journal of Pharmacology and Experimental Therapeutics, demonstrating its new class of orally administered investigational medicines elicit tissue repair in fibrotic, autoinflammatory and autoimmune conditions. The published data is preclinical and therefore still early stage, but we consider it good news as it provides the initial support to the company’s plans for additional clinical studies for Leramistat, focused on tissue repair and fibrosis. See our February 2025 update note for further background.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.